Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Z6WI
|
|||
Former ID |
DCL000796
|
|||
Drug Name |
EP-51216
|
|||
Synonyms |
(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-(4-aminobutanoylamino)-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]hexanamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Eating disorder [ICD-11: 6B82; ICD-10: F50, F98.2] | Phase 1 | [1] | |
Company |
Euro-peptides SA
|
|||
Structure |
Download2D MOL |
|||
Formula |
C46H58N10O5
|
|||
Canonical SMILES |
CC1=C(C2=CC=CC=C2N1)CC(C(=O)NC(CC3=C(NC4=CC=CC=C43)C)C(=O)NC(CC5=C(NC6=CC=CC=C65)C)C(=O)NC(CCCCN)C(=O)N)NC(=O)CCCN
|
|||
InChI |
1S/C46H58N10O5/c1-26-32(29-13-4-7-16-35(29)50-26)23-39(53-42(57)20-12-22-48)44(59)55-41(25-34-28(3)52-37-18-9-6-15-31(34)37)46(61)56-40(45(60)54-38(43(49)58)19-10-11-21-47)24-33-27(2)51-36-17-8-5-14-30(33)36/h4-9,13-18,38-41,50-52H,10-12,19-25,47-48H2,1-3H3,(H2,49,58)(H,53,57)(H,54,60)(H,55,59)(H,56,61)/t38-,39+,40-,41+/m0/s1
|
|||
InChIKey |
DFXFDNPRHWLXON-AANMMBORSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Growth hormone receptor (GHR) | Target Info | Agonist | [1] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Neuroactive ligand-receptor interaction | ||||
PI3K-Akt signaling pathway | ||||
Jak-STAT signaling pathway | ||||
Pathway Interaction Database | Notch-mediated HES/HEY network | |||
Reactome | Prolactin receptor signaling | |||
Growth hormone receptor signaling | ||||
WikiPathways | Endochondral Ossification | |||
Prolactin receptor signaling | ||||
Growth hormone receptor signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.